Overview

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

Status:
Terminated

Trial end date:
2018-12-17

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well deferasirox works in treating patients with very low, low, or intermediate-risk anemia or myelodysplastic syndrome that depends on red blood cell transfusions. Deferasirox may treat too much iron in the blood caused by blood transfusions.

Phase:

Phase 2

Details

Lead Sponsor:

Fred Hutchinson Cancer Research Center

Collaborators:

National Cancer Institute (NCI)
Novartis Pharmaceuticals

Treatments:

Deferasirox